Security key
16385C203
Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share (CMMB)
CUSIP: 16385C203
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Ordinary shares, no par value per share
- Total 13F shares
- 390,310
- Total 13F value
- $1,026,521
- Share change
- +384,560
- SEC-reported price per share
- $2.63
- Number of holders
- 10
- Value change
- +$1,011,399
- Number of buys
- 9
- Shares outstanding
- 491,982,609
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
10
Top holders
10
CMMB full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Chemomab Therapeutics Ltd. SEC filings
Chemomab Therapeutics Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 16385C203
Recent filing periods:
Ownership snapshot
Top reported holders of CMMB - Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
OrbiMed Israel BioFund GP...
Disclosed value leader
MORGAN STANLEY
Comparable rows
15/15
Latest evidence
31 Jul 2025
13D/G
13F
Lead comparable stake: 4.8%
13D/G row: OrbiMed Israel BioFund GP Limited Partnership
Showing 1-6 of 15 holder rows.
Quick read
OrbiMed Israel BioFund GP Limited Partnership leads the comparable SEC ownership view at 4.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens OrbiMed Israel BioFund GP Limited Partnership's linked filing trail.
Comparable ownership
Top 5
OrbiMed Israel BioFund GP Limited...
4.8%
SPHERA FUNDS MANAGEMENT LTD.
4.8%
MORGAN STANLEY
3.2%
ORBIMED ADVISORS LLC
0.23%
Yelin Lapidot Holdings Management...
0.14%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| OrbiMed Israel BioFund GP Limited Partnership |
13D/G
|
4.8%
|
$1,328,636
969,807 shares
|
$0 | 18 Jun 2025 |
| SPHERA FUNDS MANAGEMENT LTD. |
13D/G
13F
Company
|
4.8%
|
$1,152,548
900,428 shares
|
$0 | 31 Mar 2025 |
| MORGAN STANLEY |
13D/G
13F
Company
|
3.2%
|
$15,327,382
13,213,260 shares
|
-$22,120,527 | 31 Jul 2025 |
| ORBIMED ADVISORS LLC |
13F
Company
|
0.23%
|
$1,091,548
940,990 shares
|
— | 30 Jun 2025 |
| Yelin Lapidot Holdings Management Ltd. |
13F
Company
|
0.14%
|
$670,818
578,291 shares
|
— | 30 Jun 2025 |
| Ikarian Capital, LLC |
13F
Company
|
0.05%
|
$247,141
213,052 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
10
Shares
390,310
Rows available
10
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q1 2026 Across Filers
Q1 2026 holders
15
Q3 2025 holders
10
Holder diff
-5
| Investor | Q1 2026 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q1 2026 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend